Human Immunodeficiency Virus and Hepatitis C Virus Coinfection: Epidemiology, Natural History, Therapeutic Options and Clinical Management

Infection

Volumn 32, Issue 1, 2004, Pages 33-46

  Verucchi, G ^a   Calza, L ^a   Manfredi, R ^a   Chiodo, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALPHA INTERFERON; AMPRENAVIR; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; ERYTHROPOIETIN; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INTERFERON; NEVIRAPINE; PEGINTERFERON; RIBAVIRIN; RIBAVIRIN DERIVATIVE; STAVUDINE; ZALCITABINE; ZIDOVUDINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ARTHRALGIA; CAUSE OF DEATH; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; FATTY LIVER; FEVER; HEMOLYTIC ANEMIA; HEPATITIS A; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERSENSITIVITY; IMMUNE RESPONSE; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; MORBIDITY; MYALGIA; PANCREATITIS; PATHOGENESIS; PATIENT; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION; VIRUS TRANSMISSION;

AGE DISTRIBUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CLINICAL TRIALS; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1142273172     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-004-3063-7     Document Type: Review

References (127)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A: Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15: 347-355.
3. Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430.
4. Thomas DL: Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36 (Suppl. 1):S201-S209.
5. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2002; 32: 492-497.
6. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B: Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-247.
7. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ: Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 602-610.
8. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30: 1054-1058.
9. Sabin CA, Telfer P, Philips AN, Bhagani S, Lee CA: The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175: 164-168.
10. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
11. Ensoli F, Sirianni MC: HIV/HCV co-infection: clinical and therapeutic challenges. AIDS 2002; 16: 1419-1420.
12. Nasti G, Di Gennaro G, Tavio M, Cadorin L, Tedeschi RM, Talamini R, Carbone A, Tirelli U: Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS 2001; 15: 1783-1787.
13. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J: Management of chronic hepatitis C in HIV-infected patients. AIDS 1999; 13: 539-546.
14. Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, Martinez-Odriozola P, Colmenero M, Carballo E, Suarez D, Rodriguez-Pinero FJ, Moreno A, del Romero J, Pedreira J, Gonzalez-Lahoz J: Interferon alfa for the treatment of chronic hepatitis C in patients with HIV. Clin Infect Dis 1996; 23: 585-591.
15. Centers for Disease Control and Prevention: Updated U.S. Public Health Service guidelines on the management of occupational exposures to HBV, HCV, and HIV and recommendations for post-exposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001; 50: 1-67.
16. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL: Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35: 3274-3277.
17. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685-1690.
18. Kingsley LA, Detels R, Kaslow R, Polk BF, Rinaldo CR Jr, Chmiel J, Detre K, Kelsey SF, Odaka N, Ostrow D: Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet 1987; 1: 345-349.
19. Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorrilla C, Garcia P, Fowler MG, Mofenson L, Tuomala R: Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996; 334: 1617-1623.
20. Zanetti AR, Tanzi E, Paccagnini S, Principi N, Pizzocolo G, Caccamo ML, D'Amico E, Cambie G, Vecchi L: Mother-to-infant transmission of hepatitis C virus. Lancet 1995; 345: 289-291.
21. Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH, Hollinger FB, Davenny K, Riley L, Diaz C, Tang HB, Quinn TC: Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. J Infect Dis 1998; 177: 1480-1488.
22. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ: Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991; 115: 764-768.
23. Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, Butler K: Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000; 356: 904-907.
24. Resti M, Azzari C, Galli L, Zuin G, Giacchino R, Bortolotti F, Marcellini M, Moriondo M, de Martino M, Vierucci A: Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis 2002; 185: 567-572.
25. Sherman KE, Roustrer SD, Chung RT, Rajicic N: Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antiviral Ther 2000; 5(Suppl. 1): 64-65.
26. Waldrep TW, Summers KK, Chiliade PA: Coinfection with HIV and HCV: more questions than answers? Pharmacotherapy 2000; 20: 1499-1507.
27. Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trial Group. Clin Infect Dis 2002; 34: 831-837.
28. Sulkowski MS, Moore RD, Metha SH, Chaisson RE, Thomas DL: Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199-206.
29. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-828.
30. De Luca A, Bugarini R, Cozzi Lepri A, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Lositti G, Cadeo G, Macor A, Toti M, d'Arminio Monforte A: Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162: 2125-2132.
31. Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47: 1-40.
32. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569.
33. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ: Natural history of hepatitis C virus infection in multitransfused hemophiliacs : effect of coinfection with HIV. J Acquir Immune Defic Syndr 1993; 6: 602-610.
34. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C: The progression of HCV-associated liver disease in a cohort of hemophilic patients. Br J Haematol 1994; 87: 555-561.
35. Sanchez-Quijano A, Andreu J, Gavilan F, Luque F, Abad MA, Soto B, Muñoz J, Aznar JM, Leal M, Lissen E: Influence of HIV type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949-953.
36. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, Rey C, Abad MA, Rodriguez M, Sales Gilabert M, Gonzalez F, Miron P, Caruz A, Relimpio F, Torronteras R, Leal M, Lissen E: HIV infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
37. Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR: The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94: 746-752.
38. Pol S, Fontaine H, Carnot F, Zylberberg H, Berthelot P, Bréchot C, Nalpas B: Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998; 29: 12-19.
39. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM: Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179: 1254-1258.
40. Puoti M, Bonacini M, Spinetti A, Putzolu V, Govindarajan S, Zaltron S, Favret M, Callea F, Gargiulo F, Donato F, Carosi G: Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and HIV. J Infect Dis 2001; 183: 134-137.
41. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G: Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-1214.
42. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M: Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 33: 1793-1794.
43. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, Quiros-Roldan E, Zanini B, Casari S, Carosi G: Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24: 211-217.
44. Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V, Soriano V: Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-183.
45. Rockstroh JK, Theisen A, Kaiser R, Sauerbruch T, Spengler U: Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs. AIDS 1998; 12: 829-830.
46. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D, Marcellin P: The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34: 1193-1199.
47. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, Cheung L, Nelson KE: Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996; 174: 690-695.
48. Beld M, Penning M, Lukashov V, McMorrow M, Roos M, Pakker N, van den Hoek A, Goudsmit J: Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 1998; 244: 504-512.
49. Ghany MG, Leissinger C, Lagier R, Sanchez-Pescador R, Lok ASF: Effect of human immunodeficiency virus infection on hepatitis C virus Infection in hemophiliacs. Dig Dis Sci 1996; 41: 1265-1272.
50. Soriano V, Bravo R, Mas A, Garcia-Samaniego J, Guierrez M, Gonzalez-Lahoz J: Impact of immunosuppression caused by HIV infection on the replication of hepatitis C virus. Vox Sang 1995; 69: 259-260.
51. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F: High hepatitis C viremia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9: 1131-1136.
52. Mehta SH, Cox A, Hoover DR, Wang XH, Mao O, Ray S, Strathdee SA, Vlahov D, Thomas DL: Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-1483.
53. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456.
54. Lauer GM, Nguyen TN, Day CL, Robbins GK, Flynn T, McGowan K, Rosenberg ES, Lucas M, Klenerman P, Chung RT, Walker BD: Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 2002; 76: 2817-2826.
55. Lafon ME, Kirn A: Human immunodeficiency virus infection of the liver. Semin Liver Dis 1992; 12: 197-204.
56. Talal AH, Canchis PW, Jacobson I: The HCV and HIV coinfected patient: what have we learned about pathophysiology? Curr Gastroenterol Rep 2002; 4: 15-22.
57. Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S: Rapidly evolving hepatitis C virus-related cirrhosis in HIV-infected patients receiving triple antiretroviral therapy. Clin Infect Dis 1998; 27: 1255-1258.
58. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E: Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral therapy. AIDS 1998; 12: 116-117.
59. Rutschmann O, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin L: Impact of antiretroviral treatment with HIV protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177: 783-785.
60. Ragni M, Bontempo F: Increase in hepatitis C virus load in hemophiliacs during treatment with HAART. J Infect Dis 1999; 180: 2027-2029.
61. Perez-Olmeda M, Garcia-Samaniego J, Soriano V: Hepatitis C viremia in HIV-HCV coinfected patients having immune restoration with HAART. AIDS 2000; 14: 212.
62. Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE: Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16: 1915-1923.
63. Torre D, Tambini R, Cadario F, Barbarini G, Moroni M, Basilico C: Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2001; 33: 1579-1585.
64. Gavazzi G, Bouchard O, Leclercq P, Morel-Baccard C, Bosseray A, Dutertre N, Micoud M, Morand P: Change in transaminases in hepatitis C virus-and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders? AIDS Res Hum Retrovirus 2000; 16: 1021-1023.
65. John M, Flexman J, French M: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV-protease inhibitors: an immune restoration disease? AIDS 1998; 12: 2289-2293.
66. Cribier B, Schmitt C, Rey D, Lang JM, Kirn A, Stoll-Keller F: Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV. Res Virol 1996; 47: 263-266.
67. Babik JM, Holodniy M: Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasi-species diversity in human immunodeficiency virus/hepatitis C virus coinfected patients. J Virol 2003; 77: 1940-1950.
68. Yokozaki S, Takamatsu J, Nakano I, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Fukuda Y: Immunologic dynamics in haemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000; 96: 4293-4299.
69. Cooper CL, Cameron DW: Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002; 35: 873-879.
70. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
71. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, Poynard T: Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus co-infected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-287.
72. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182-188.
73. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
74. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31.
75. Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ: Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis 2000; 31: 1234-1239.
76. Bonfanti P, Landonio S, Ricci E, Martinelli C, Fortuna P, Faggion I, Quirino T: Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 316-318.
77. d'Arminio Monforte A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, Vigevani GM, Tirelli U, Bruno R, Gritti F, Piazza M, Chigiotti S, Chirianni A, De Stefano C, Pizzigallo E, Perrella O, Moroni M: Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28: 114-123.
78. Aceti A, Pasquazzi C, Zechini B, De Bac C: Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. J Acquir Immune Defic Syndr 2002; 29: 41-48.
79. Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J Jr, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L: Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. Ann Intern Med 1997; 126: 355-363.
80. Lenzo NP, Garas BA, French MA: Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS 1997; 11: 1294-1296.
81. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V: Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998; 12: 1256.
82. Savés M, Vandentorren S, Daucourt V, Marimoutou C, Dupon M, Couzigou P, Bernard N, Mercie P, Dabis F: Severe hepatic cytolisis: incidence and risk factors in patients treated with antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. AIDS 1999; 13: F115-F121.
83. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895-2902.
84. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V: Risk factors for severe liver toxicity following the introduction of HAART. J Acquir Immune Defic Syndr 2001; 27: 426-431.
85. Spengler U, Lichterfeld M, Rockstroh JK: Antiretroviral drug toxicity - a challenge for the hepatologist? J Hepatol 2002; 36: 283-294.
86. Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430.
87. Coopman MA, Johnson RA, Platt R, Stern RS: Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328: 1670-1674.
88. Kakuda TN: Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
89. Riddle TM, Kuhel DG, Woollett LA, Fichtembaum CJ, Hui DY: HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276: 37514-37519.
90. van Heeswijk RP, Veldkamp AI, Hoetelmans RM, Mulder JW, Schreij G, Hsu A, Lange JM, Beijnen JH, Meenhorst PL: The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily regimens in HIV-1-infected individuals. AIDS 1999; 13: 95-99.
91. Sobue S, Nomura T, Ishikawa T, Ito S, Saso K, Ohara H, Joh T, Itoh M, Kakumu S: Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol 2001; 36: 544-551.
92. Martin-Carbonero L, Nunez M, Rios P, Perez-Olmeda M, Gonzalez-Lahoz J, Soriano V: Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 2002; 16: 1423-1425.
93. Nunez M, Rios P, Martin-Carbonero L, Perez-Olmeda M, Gonzalez-Lahoz J, Soriano V: Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30: 65-68.
94. Davis GL: Hepatitis C virus genotypes and quasispecies. Am J Med 1999; 107: 21S-26S.
95. Rancinan C, Neau D, Savés M, Lawson-Ayayi S, Bonnet F, Mercié P, Dupon M, Couzigou P, Dabis F, Chêne G: Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated with combination antiretroviral therapy? AIDS 2002; 16: 1357-1362.
96. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furher J, McCabe RE, Wood KC, Holmberg SD: Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36: 363-367.
97. Quan CM, Krajden M, Grigoriew GA, Salit IE: Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993; 17: 117-119.
98. Dorrucci M, Pezzoti P, Philips AN, Cozzi L, Rezza G: Coinfection of hepatitis C virus with immunodeficiency virus and progression to AIDS. J Infect Dis 1995; 172: 1503-1508.
99. Staples CT, Rimland D, Dudas D: Hepatitis C in the human immunodeficiency virus Atlanta V.A. (Veterans Affair Medical Center) cohort study (HAVACS): the effect of co-infection on survival. Clin Infect Dis 1999; 29: 150-154.
100. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, Grappin M, Buisson M, Waldner A, Portier H, Chavanet P: Does hepatitis C virus coinfection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998; 12: 381-388.
101. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM: Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus positive hemophilics and should be treated as an opportunistic infection. J Infect Dis 1999; 179: 1254-1258.
102. Boyer N, Marcellin P, Degott C, Degos F, Saimot AG, Erlinger S, Benhamou JP: Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to HIV. J Infect Dis 1992; 165: 723-726.
103. Marriott E, Navas S, del Romero J, Garcia S, Castillo I, Quiroga JA, Carreno V: Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Virol 1993; 40: 107-111.
104. Mauss S, Klinker H, Ulmer A, Willers R, Weissbrich B, Albrecht H, Haussinger D, Jablonowski H: Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998; 26: 16-19.
105. Soriano V, Bravo R, Garcia-Samaniego J, Ortega E, Gonzalez J, Colmenero M, Castilla J, Castro A, Suarez D: A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. The Hepatitis/HIV Spanish Study Group. J Infect 1997; 35: 225-230.
106. Prestileo T, Mazzola G, Di Lorenzo F, Colletti P, Vitale F, Ferraro D, Di Stefano R, Camma C, Craxi A: Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients. Int J Antimicrob Agents 2000; 16: 373-378.
107. Landau A, Batisse D, Van Huyen JP, Piketty C, Bloch F, Pialoux G, Belec L, Petite JP, Weiss L, Kazatchkine MD: Efficacy and safety of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2000; 14: 839-844.
108. Nasti G, di Gennaro G, Rizzardini G, Cadorin L, Tirelli U: Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-alpha 2b and ribavirin combination therapy. J Acquir Immune Defic Syndr 2001; 26: 299-300.
109. Suciu L, Goldman D, Jones J, Weisz K, Dieterich D: Sustained virologic response following interferon and ribavirin therapy for hepatitis C patients who are co-infected with HIV [abstr]. 38th IDSA, New Orleans, 2000.
110. Sauleda S, Juarez A, Esteban JI, Altisent C, Ruiz I, Puig L, Esteban R, Guardia J: Interferon and ribavirin combination therapy for chronic hepatitis C in HIV-infected patients with congenital coagulation disorders. Hepatology 2001; 34: 1035-1040.
111. Kostman JR, Rodriguez-Torres M, Prokupek D, Brau N, Bonacini M, Hassanein T, Smith J: Results of a multicenter, randomized, double-blind, controlled trial of interferon alfa-2b/ribavirin combination therapy in HCV/HIV coinfected persons [abstr]. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, 2001.
112. Landau A, Batisse D, Piketty C, Jian R, Kazatchkine M: Lack of interference between ribavirin and nucleoside analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000; 14: 1857-1858.
113. Bochet M, De Torres M, Valantin M: Efficacy and tolerance of interferon plus ribavirin for chronic hepatitis C in HIV-infected patients [abstr]. In: 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 2001.
114. Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, Poynard T, Katlama C, Pialoux G, Brechot C, Pol S: Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47: 694-697.
115. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b in combination with ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial. Lancet 2001; 358: 958-965.
116. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
117. Chung R, Andersen J, Alston B: A randomized, controlled trial of pegylated interferon alpha-2a with ribavirin vs. interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071 [abstr]. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002.
118. Rockstroh JK, Mudar M, Lichterfeld M, Nischalke HD, Klausen G, Golz J, Dupke S, Notheis G, Stein L, Mauss S: Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS 2002; 16: 2083-2085.
119. Perez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR, Pedreira J, Barreiro P, Garcia-Samaniego J, Martin-Carbonero L, Jimenez-Nacher I, Soriano V: Pegylated IFN-alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17: 1023-1028.
120. Perrone C, Carrat F, Bani Sadr F, for the ANRS HCO2 Study Group: RIBAVIC Trial: a controlled randomized trial of pegylated-interferon alfa-2b plus ribavirin vs. interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV coinfected patients. Preliminary results [abstr]. 14th International AIDS Conference, Barcelona, 2002.
121. Poles M, Dieterich D: Hepatitis C/HIV coinfection: clinical management issues. Clin Infect Dis 2000; 31: 154-161.
122. Lafeuillade A, Hittinger G, Chapadaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-281.
123. Morsica G, De Bona A, Uberti C, Sitia G, Finazzi R, Lazzarin A: Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. AIDS 2000; 14: 1656-1658.
124. Vento S, Di Perri G, Cruciani M, Garofano T, Concia E, Bassetti D: Rapid decline of CD4+ cells after interferon treatment in HIV-1 infection. Lancet 1993; 341: 958-989.
125. Pesce A, Taillan B, Rosenthal E: Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993; 341: 1597.
126. Hadziyannis SJ, Papatheodoridis GV: Peginterferon-alpha2a (40kDa) for chronic hepatitis C. Expert Opin Pharmacother 2003; 4: 541-551.
127. Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138: 197-207.